IEFA, SPOT, SE, TEVA: Large Inflows Detected at ETF
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Source: NASDAQ.COM
52 Week Range and Current Price: The IEFA ETF has a 52-week low of $66.95 and a high of $78.9464, with the last trade recorded at $74.21.
ETF Trading Dynamics: ETFs operate like stocks but involve trading "units" that can be created or destroyed based on investor demand, affecting the underlying holdings and market flows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.560
Low
29.00
Averages
35.71
High
40.00
Current: 34.560
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
- Stock Price Recovery: Teva Pharmaceutical's stock has surged by 97% over the past year, indicating a significant recovery from previous challenges including debt and litigation, although the current price may not present an ideal buying opportunity.
- Biosimilars Market: Teva has launched two biosimilars in partnership with Alvotech, namely Simlandi in May 2024 and Selarsdi in February 2025, with expectations for its biosimilars business to double to around $800 million by 2027, despite facing fierce competition and narrow profit margins.
- Branded Drug Performance: The company's resurgence is primarily driven by its branded drugs, particularly Austedo, which achieved approximately $2.3 billion in sales in 2025, highlighting strong demand in treating movement disorders, although overall revenue is projected to be flat or decline in 2026.
- Investor Caution: Despite the evident recovery, Teva's current P/E ratio of about 25 suggests that its valuation is no longer attractive, prompting investors to carefully assess future growth potential, especially as better investment opportunities may exist in other areas of the pharmaceutical industry.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Teva Completes Acquisition of Emalex Biosciences for $700 Million
- Acquisition Completed: Teva Pharmaceutical has finalized its acquisition of Emalex Biosciences for $700 million, with potential additional commercial milestone payments of up to $200 million, thereby enhancing Teva's market position in the pediatric Tourette syndrome sector.
- New Drug Asset: The acquisition adds Ecopipam, an investigational drug targeting pediatric Tourette syndrome, to Teva's pipeline, designed to block dopamine signaling at the D1 receptor through selective dopamine antagonism.
- Successful Clinical Trials: Ecopipam met its primary efficacy endpoint in a Phase 3 trial by significantly reducing relapse time for pediatric patients, demonstrating good tolerability, which lays a solid foundation for future market introduction.
- FDA Approval Anticipation: Teva plans to submit a New Drug Application for Ecopipam in the second half of 2026, which could further drive the company's growth potential in the pediatric pharmaceutical market.
See More
Teva Acquires Emalex Biosciences to Enhance Pipeline for Tourette Syndrome
- Acquisition Details: Teva's acquisition of Emalex Biosciences for $700 million, with potential additional payments of up to $200 million upon achieving commercial milestones, underscores Teva's strategic intent to expand in the neuroscience sector.
- Innovative Drug Development: Ecopipam, a first-in-class selective dopamine D1 receptor antagonist, has received FDA Orphan Drug and Fast Track designations, expected to address a significant unmet need in pediatric Tourette syndrome treatment, fulfilling urgent market demands.
- Clinical Trial Results: Phase 3 trial results for ecopipam demonstrated statistical significance (p = 0.0084) between the treatment and placebo groups on the primary efficacy endpoint, laying a solid foundation for the drug's commercialization.
- Strategic Transformation: This acquisition aligns with Teva's
See More
Alvotech's AVT16 Biosimilar Application Accepted by FDA
- FDA Acceptance Milestone: Alvotech's Biologics License Application for AVT16 has been accepted by the FDA, marking a significant step in the company's mission to enhance global access to biologic medicines, which is expected to strengthen its market competitiveness.
- Strategic Partnership: Under its collaboration with Teva Pharmaceuticals, Alvotech is responsible for the development and manufacturing of AVT16, while Teva handles commercialization, a division of labor that will help expedite product launch and expand market reach.
- Biosimilar Benefits: As an interchangeable biosimilar to Entyvio, AVT16 could provide more options for patients and healthcare providers in the U.S. if approved, further driving the growth of the biosimilar market.
- Positive Market Reaction: Alvotech shares rose 12% in premarket trading to $3.97, reflecting investor optimism regarding the FDA acceptance news, which may indicate future growth potential.
See More
Teva Reports New Efficacy Data for Huntington's Disease Treatments
- Clinical Study Results: Teva Pharmaceutical Industries presented new data at the 2026 Advanced Therapeutics in Movement & Related Disorders congress, demonstrating significant efficacy of AUSTEDO and AUSTEDO XR in improving quality of life for Huntington's disease patients.
- Positive Patient Feedback: Following treatment with AUSTEDO or AUSTEDO XR, 77% of patients reported improvements in chorea symptoms on the Patient Global Impression of Change (PGIC) scale, indicating the drugs' effectiveness in symptom relief.
- Quality of Life Improvement: Over 85% of patients noted that treatment improved their goals related to basic daily activities, while 77% experienced enhancements in social life, including better emotional well-being and reduced stress and emotional burden.
- Market Reaction: Although Teva's stock closed down 0.70% on Friday, the release of this new data may positively influence future market performance, particularly in the growing field of Huntington's disease treatment.
See More
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
- Stock Price Recovery: Teva Pharmaceutical's stock has surged by 97% over the past year, indicating a significant recovery from previous challenges including debt and litigation, although the current price may not present an ideal buying opportunity.
- Biosimilars Market: Teva has launched two biosimilars in partnership with Alvotech, namely Simlandi in May 2024 and Selarsdi in February 2025, with expectations for its biosimilars business to double to around $800 million by 2027, despite facing fierce competition and narrow profit margins.
- Branded Drug Performance: The company's resurgence is primarily driven by its branded drugs, particularly Austedo, which achieved approximately $2.3 billion in sales in 2025, highlighting strong demand in treating movement disorders, although overall revenue is projected to be flat or decline in 2026.
- Investor Caution: Despite the evident recovery, Teva's current P/E ratio of about 25 suggests that its valuation is no longer attractive, prompting investors to carefully assess future growth potential, especially as better investment opportunities may exist in other areas of the pharmaceutical industry.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Teva Completes Acquisition of Emalex Biosciences for $700 Million
- Acquisition Completed: Teva Pharmaceutical has finalized its acquisition of Emalex Biosciences for $700 million, with potential additional commercial milestone payments of up to $200 million, thereby enhancing Teva's market position in the pediatric Tourette syndrome sector.
- New Drug Asset: The acquisition adds Ecopipam, an investigational drug targeting pediatric Tourette syndrome, to Teva's pipeline, designed to block dopamine signaling at the D1 receptor through selective dopamine antagonism.
- Successful Clinical Trials: Ecopipam met its primary efficacy endpoint in a Phase 3 trial by significantly reducing relapse time for pediatric patients, demonstrating good tolerability, which lays a solid foundation for future market introduction.
- FDA Approval Anticipation: Teva plans to submit a New Drug Application for Ecopipam in the second half of 2026, which could further drive the company's growth potential in the pediatric pharmaceutical market.
See More
Teva Acquires Emalex Biosciences to Enhance Pipeline for Tourette Syndrome
- Acquisition Details: Teva's acquisition of Emalex Biosciences for $700 million, with potential additional payments of up to $200 million upon achieving commercial milestones, underscores Teva's strategic intent to expand in the neuroscience sector.
- Innovative Drug Development: Ecopipam, a first-in-class selective dopamine D1 receptor antagonist, has received FDA Orphan Drug and Fast Track designations, expected to address a significant unmet need in pediatric Tourette syndrome treatment, fulfilling urgent market demands.
- Clinical Trial Results: Phase 3 trial results for ecopipam demonstrated statistical significance (p = 0.0084) between the treatment and placebo groups on the primary efficacy endpoint, laying a solid foundation for the drug's commercialization.
- Strategic Transformation: This acquisition aligns with Teva's
See More
Alvotech's AVT16 Biosimilar Application Accepted by FDA
- FDA Acceptance Milestone: Alvotech's Biologics License Application for AVT16 has been accepted by the FDA, marking a significant step in the company's mission to enhance global access to biologic medicines, which is expected to strengthen its market competitiveness.
- Strategic Partnership: Under its collaboration with Teva Pharmaceuticals, Alvotech is responsible for the development and manufacturing of AVT16, while Teva handles commercialization, a division of labor that will help expedite product launch and expand market reach.
- Biosimilar Benefits: As an interchangeable biosimilar to Entyvio, AVT16 could provide more options for patients and healthcare providers in the U.S. if approved, further driving the growth of the biosimilar market.
- Positive Market Reaction: Alvotech shares rose 12% in premarket trading to $3.97, reflecting investor optimism regarding the FDA acceptance news, which may indicate future growth potential.
See More
Teva Reports New Efficacy Data for Huntington's Disease Treatments
- Clinical Study Results: Teva Pharmaceutical Industries presented new data at the 2026 Advanced Therapeutics in Movement & Related Disorders congress, demonstrating significant efficacy of AUSTEDO and AUSTEDO XR in improving quality of life for Huntington's disease patients.
- Positive Patient Feedback: Following treatment with AUSTEDO or AUSTEDO XR, 77% of patients reported improvements in chorea symptoms on the Patient Global Impression of Change (PGIC) scale, indicating the drugs' effectiveness in symptom relief.
- Quality of Life Improvement: Over 85% of patients noted that treatment improved their goals related to basic daily activities, while 77% experienced enhancements in social life, including better emotional well-being and reduced stress and emotional burden.
- Market Reaction: Although Teva's stock closed down 0.70% on Friday, the release of this new data may positively influence future market performance, particularly in the growing field of Huntington's disease treatment.
See More
